PACB Stock Analysis: Buy, Sell, or Hold?
PACB - Pacific Biosciences of California, Inc.
$1.99
-0.06 (-2.93%)
▼
5d:
-26.84%
30d:
+48.51%
90d:
+33.56%
WAIT
LOW Confidence
Analysis Updated: Oct 14, 2026 12:00 AM ET
Earnings: Nov 04, 2026
19d
Get Alerted When PACB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: PACB is down 26.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: PACB is down 26.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: PACB is currently trading at $1.99, which is considered fair relative to its 30-day fair value range of $1.31 to $2.35.
Technical Outlook: Technically, PACB is in a uptrend. The price is currently testing key support at $1.95. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PACB scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $2.40 (+20.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PACB is in a uptrend. The price is currently testing key support at $1.95. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PACB scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $2.40 (+20.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.31 -
$2.35
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
Protect Your Profits
Holding PACB? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 20.6% below Wall St target ($2.40)
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.31 -
$2.35
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.95
Resistance Level
$3.44
Current Trend
Uptrend
Technical data as of
Oct 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.72
Wall Street Target
$2.40
(+20.6%)
Revenue Growth (YoY)
-1.9%
Profit Margin
-82.5%
Share & Embed Analysis
Last updated: October 15, 2026 12:14 AM ET
Data refreshes hourly during market hours. Next update: 1:14 AM
Data refreshes hourly during market hours. Next update: 1:14 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PACB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
31 analysts |
$60 | 61 BUY |
|
EW
Edwards Lifesciences Corp |
STRONG BUY
29 analysts |
$102 | 66 BUY |
|
ABT
Abbott Laboratories |
STRONG BUY
28 analysts |
$121 | 61 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
29 analysts |
$96 | 49 HOLD |
|
SYK
Stryker Corporation |
STRONG BUY
29 analysts |
$364 | 53 HOLD |
Advanced PACB Option Strategies
Professional options setups generated by AI based on today's PACB price and gamma walls.
